Skip to main content Skip to section navigation Skip to footer

Home
Our story
Our focus
Our portfolio
For investors
- Company
- Stock
- SEC filings
- Governance
- Analysts
- News
- Events
Contact us
Sign up for email alerts

Events

For investors

Company
Stock
SEC filings
Governance
Analysts
News
Events

Relmada Therapeutics, Inc.

Events

Relmada Results of Human Abuse Potential Study of REL-1017 vs. Ketamine

Feb 23, 2022 8:30 am EDT

Webcast

Audio

Email Alerts
RSS News Feed

Sign up for alerts

Our story
Our focus
Our portfolio
For investors
- Company
- Stock
- SEC filings
- Governance
- Analysts
- News
- Events
Contact us

©2023 Relmada Therapeutics, Inc.